Behavioral effects of photothrombotic ischemic cortical injury in aged rats treated with the sedative-hypnotic GABAergic drug zopiclone.
Sedative-hypnotic drugs commonly used in the elderly may affect functional recovery following cerebrovascular events. Previous research has shown that prolonged exposure to diazepam can interfere with recovery of function and exaggerate tissue loss after brain injury. The present study evaluated the effect of zopiclone, a widely used hypnotic drug, on functional and histological outcome after cortical photothrombosis in aged rats, which might be particularly vulnerable to brain insults and inhibitory sedative-hypnotic drugs. Aged Wistar rats were treated with zopiclone at a dose of 3 mg/kg (i.p., once a day) beginning 4 days before ischemia induction and continuing for 23 days. Sensorimotor recovery was assessed by a new ledged beam-walking test and spatial learning by the Morris water-maze. After a 7-day washout period all rats were administered a single dose of zopiclone (3 mg/kg, i.p.) and retested. Infarct volumes were measured from nitroblue tetrazolium-stained sections at the end of the experiment. Beam-walking data showed that ischemic rats treated with zopiclone were not more impaired than untreated rats. Indeed, they showed fewer faults with the impaired hindlimb than ischemic controls on post-operative day 16. Water-maze performance was not affected by zopiclone. After the washout period a single dose of zopiclone did not worsen forelimb or hindlimb function, but seemed to improve performance in the water-maze test. Cortical infarct volumes were similar in ischemic controls and ischemic rats treated with zopiclone. In conclusion, zopiclone was not detrimental and even seemed to improve behavioral outcome without affecting ischemic damage in aged rats subjected to cortical photothrombosis.
Zhao
Chuan-sheng
CS
Department of Neuroscience and Neurology, University of Kuopio, Finland.
Puurunen
Kirsi
K
Schallert
Timothy
T
Sivenius
Juhani
J
Jolkkonen
Jukka
J
D000375:Aging / Q000502:physiology*; D000704:Analysis of Variance; D000818:Animals; D053961:Azabicyclo Compounds; D001522:Behavior, Animal / Q000502:physiology*; D001930:Brain Injuries / Q000188:drug therapy* / Q000209:etiology; D002540:Cerebral Cortex / Q000473:pathology; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D020925:Hypoxia-Ischemia, Brain / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D020767:Intracranial Thrombosis / Q000150:complications; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D009580:Nitroblue Tetrazolium; D010777:Photochemistry; D010879:Piperazines / Q000627:therapeutic use*; D011597:Psychomotor Performance / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time / Q000187:drug effects; D013997:Time Factors
D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; C515050:zopiclone; D009580:Nitroblue Tetrazolium